---
title: "Inspire Medical shares fall after disclosure of DoJ investigation"
date: "2025-02-11 01:06:44"
summary: "Despite strong 2024 Q4 results that beat on both lines, Inspire Medical Systems (NYSE:INSP) is down ~5% in after-hours trading Monday after disclosing a civil investigative demand from the DoJ's U.S. Attorney's Office in Minnesota. The DoJ stated that the request is related to \"allegations of false claims, including false..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219178838/image_1219178838.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Despite strong 2024 Q4 results that [beat on both lines](https://seekingalpha.com/news/4405787-inspire-medical-systems-gaap-eps-of-1_15-beats-by-0_43-revenue-of-239_72m-beats-by-2_31m "beat on both lines"), Inspire Medical Systems (NYSE:[INSP](https://seekingalpha.com/symbol/INSP "Inspire Medical Systems, Inc.")) is down ~5% in after-hours trading Monday after disclosing a civil investigative demand from the DoJ's U.S. Attorney's Office in Minnesota.
* The DoJ stated that the request is related to "allegations of false claims, including false claims arising from violations of the Anti-Kickback Statute, submitted to government payors in connection with our implant." Inspire manufactures an implantable device used to treat sleep apnea.
* A 10-K [filing](https://seekingalpha.com/filing/9531729 "filing") states that the DoJ is seeking information regarding marketing, promotion and reimbursement practices, and Inspire is cooperating.
* Inspire also reiterated 2025 revenue guidance of $940M-$950M. Consensus is $948.66M. The company also set 2025 diluted EPS at $2.10-$2.20. Consensus is $1.94.

[seekalpha](https://seekingalpha.com/news/4405844-inspire-medical-shares-fall-after-disclosure-doj-investigation)
